“…In contrast, oximes either do not enter the brain at all, or only a very small percentage passes the blood-brain barrier Lorke, Kalasz, Petroianu, & Tekes, 2008). K-27 belongs to a group of newly developed oxime-type AChE reactivators (Kuča et al, 2010;Kuča & Cabal, 2004;Kuča, Cabal, & Kassa, 2005;Kuča & Kassa, 2004;Lorke, Nurulain, et al, 2008;Petroianu, Lorke, & Kalasz, 2012), which efficiently reduce OPCinduced mortality, when administered after OPC exposure (Kassa, Kuča, Cabal, & Paar, 2006;Lorke, Kalasz, et al, 2008;Nurulain et al, 2009;. These K-oximes include K-27, K-48 and K-203 ( Figure 1), bisquaternary asymmetric pyridinium aldoximes containing only one functional aldoxime group in position 4 of the pyridine ring (Kassa et al, 2006;Kuča, Bielavsky, Cabal, & Bielavska, 2003) as well as K-53, K-74 and K-75, bispyridinium oximes with two aldoxime groups Musilek et al, 2007).…”